TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30632413
Drug: Carbohydrate beverage
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate beverage (0.5 g·kg‐1·day‐1)
Study: 26391570
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone treatment (75 mg per day for 90 days)
Study: 11157586
Drug: Long-term exercise
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term exercise therapy (18 months)
Study: 27315831
Drug: Basic SMS
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic SMS reminder repeating the RDT result and appropriate treatment actions
Study: 3903788
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg penbutolol alone
Study: 3142454
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (12 young men) using a device supplying 12.8% O2 for 7.5-8 hours daily for 10 days.
Study: 30223315
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 8 mg (IV)
Study: 29872148
Drug: TEFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEFOX regimen (docetaxel 50 mg/m2, oxaliplatin 85 mg/m2, 5FU 2400 mg/m2) administered every 14 days
Study: 23293111
Drug: Sequential docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential docetaxel (A (75 mg/m(2)) × 3 → docetaxel (T (100 mg/m(2)) × 3 → CMF)
Study: 16542199
Drug: Topical ibuprofen
Normalized name: ibuprofen Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ibuprofen
Study: 16601430
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg PPS 3 times per day (300 mg/day)
Study: 28283732
Drug: half-dose photodynamic
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: half-dose photodynamic therapy (hd-PDT)
Study: 3287813
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 50 mg indomethacin
Study: 3287813
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of 100 mg indomethacin
Study: 379049
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide mouthwash (Amosan), 1.7 g powder dissolved in 30 ml hot tap water, rinsed after meals for 2 weeks
Study: 17997772
Drug: Hot compresses
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot compresses (conservative treatment)
Study: 16329018
Drug: Physostigmine 10
Normalized name: PHYSOSTIGMINE
DrugBank: Physostigmine (DB00981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 10 micrograms/kg intravenously followed by meperidine 0.5 mg/kg intravenously (group 2)
Study: 10436259
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Gliclazide
Study: 8828533
Drug: Oral budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral budesonide
Study: 31187264
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal cannula at 4 L/min
Study: 31187264
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow nasal cannula at 6 L/min
Study: 30639763
Drug: Tablet-based screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based screening
Study: 12877822
Drug: Zafirlukast 40
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zafirlukast 40 mg
Study: 2270301
Drug: Heparin lock
Normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin lock changed every 72 hours (Group A)
Study: 2270301
Drug: Heparin lock
Normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin lock left in place up to 168 hours (Group B)
Study: 8201130
Drug: 15-min exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-min exposure to light daily
Study: 30027479
Drug: New mint-flavored
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: New mint-flavored nicotine gum (2 mg)
Study: 28002167
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg intravenously
Study: 16439495
Drug: Daily activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activity recording for 6 weeks
Study: 6175136
Drug: Halcinonide cream
Normalized name: Halcinonide Cream
DrugBank: Halcinonide (DB06786)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halcinonide cream (Halog) 0.1% (50 micrograms)
Study: 3405343
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (adjuvant chemotherapy with cyclophosphane, methotrexate, 5‐fluorouracil)
Study: 21607794
Drug: Mosapride 15
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride 15 mg by mouth three times a day starting on postoperative day 1
Study: 10086255
Drug: Internal medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal medicine return visits
Study: 11870439
Drug: Low-dose FDT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose FDT (S800, n=25)
Study: 17006287
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine alone (dose 1)
Study: 17006287
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine concomitantly with other vaccines
Study: 20538418
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg, 4 times/day
Study: 20538418
Drug: Morphine 15
Normalized name: morphine 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 15 mg, 4 times/day
Study: 1773780
Drug: CBZ 600
Normalized name: CBZ
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBZ 600 mg
Study: 17138642
Drug: Ketoprofen patch
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen patch 100 mg once daily
Study: 18469247
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (5 mg/kg) with high glycemic index meal
Study: 2567431
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of salbutamol in 2 ml (0.5 mg) of preservative‐free ipratropium bromide
Study: 31559532
Drug: sc IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc IFN β‐1a 44 µg tiw
Study: 15310446
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural blockade with bupivacaine 0.25% (10 mg bolus and 5 mg/h continuous infusion)
Study: 2530507
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion (5%)
Study: 9931893
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy (50.4 Gy) and 12 cycles of 5‐fluorouracil and medium‐dose folinic acid
Study: 9931893
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy (50.4 Gy) and 6 cycles of 5‐fluorouracil and medium‐dose folinic acid
Study: 2838151
Drug: Single-dose dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose dactinomycin (60 micrograms/kg, later reduced to 45 micrograms/kg)
Study: 16776894
Drug: Special intervention
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special intervention (individual counseling visit, twelve group sessions, three postcard messages, twelve monthly telephone calls)
Study: 8751743
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (alpha‐tocopherol) 200 mg daily by mouth for 3 months
Study: 30052571
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (LGG) supplementation (10 billion colony-forming units daily for 6 months)
Study: 18684176
Drug: Direct Observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Observed Therapy (DOT)
Study: 18684176
Drug: Self-Administration (SA)
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Administration (SA)
Study: 16395298
Drug: Modafinil 400
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 400 mg
Study: 1792400
Drug: Thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental 5 mg/kg
Study: 2058666
Drug: Chloroquine phosphate,
Normalized name: Chloroquine Phosphate, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine phosphate, 250 mg four times daily for 3 days
Study: 28560503
Drug: Diet supplemented
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet supplemented with an additional 480 g of fruit and vegetables and 300 ml of fruit juice daily for 12 weeks
Study: 25317365
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg once daily
Study: 16145317
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50 microg/day) continuously and transdermal norethisterone (250 microg/day for 14 days of every 28‐day cycle)
Study: 16145317
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol and norethisterone
Study: 9695722
Drug: Urodilatin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urodilatin infusion (7.5 to 15 to 30 ng.kg body weight‐1.min‐1)
Study: 12627187
Drug: Increased folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased folate intake through diet and supplement (400 microg folic acid)
Study: 7941942
Drug: Ibuprofen 40
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 40 mg.kg‐1.d‐1, divided into four equal doses
Study: 12624551
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (4 mg.kg(‐1) thiopental and 1.5 mg.kg(‐1) succinylcholine)
Study: 16244520
Drug: Intramuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular electrical stimulation
Study: 7992066
Drug: Hyperfractionated accelerated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated accelerated radiotherapy (2 x 1.6 Gy/d 5 days per week; total dose, 64 to 67.2 Gy) plus simultaneous intravenous carboplatin (60 mg/m2, days 1-5 and 29-33)
Study: 9457403
Drug: Inhaled IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled IL-2 therapy (high-dose inhalation)
Study: 24535888
Drug: Fexinidazole loading
Normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexinidazole loading dose of 1,800 mg/day for 4 days followed by 1,200 mg/day for 6 days with a normal meal
Study: 22721971
Drug: IL-2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 therapy
Study: 7661476
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia and postoperative patient-controlled intravenous narcotic analgesia (GEN)
Study: 9421122
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with ranitidine 300 mg b.i.d and clarithromycin 750 mg b.i.d, plus placebo (Group A)
Study: 2746493
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose lorazepam (0.045 mg/kg)
Study: 19056608
Drug: Hypoglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic clamp (2.8 mmol/l)
Study: 11437980
Drug: Caloric liquid
Normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric liquid meal with paracetamol administered orally with nasogastric tube
Study: 26410620
Drug: dacarbazine 1000
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dacarbazine 1000 mg/m² every 3 weeks
Study: 17049060
Drug: MMF with
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF with 50% dose reduction of CsA
Study: 2233278
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐estradiol plus 1 mg norethisterone acetate daily for 1 year
Study: 2233278
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets for 1 year
Study: 25519029
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) administration
Study: 8418401
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical treatment alone (medical group; n=233)
Study: 21443601
Drug: Alitretinoin 30
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alitretinoin 30 mg and ketoconazole 200 mg
Study: 15504127
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg b.i.d. (single-day oral treatment)
Study: 1796238
Drug: Quinine 10
Normalized name: quinine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 10 mg/kg body weight once daily for 3 days
Study: 3914180
Drug: Vitamin B-6
Normalized name: Vitamin B-6 100mg Tablet
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-6 100 mg daily and Placebo
Study: 11535961
Drug: Antidepressants or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants or counselling
Study: 8856392
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test (OGTT) in obese patients
Study: 25256660
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg via subcutaneous injection into the abdomen
Study: 25256660
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg via subcutaneous injection (all sites)
Study: 450561
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of vitamin E (10 mg/kg/day) to safflower oil
Study: 24382095
Drug: Early-onset alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early-onset alcohol and drug users (n=122; 67%)
Study: 6990875
Drug: Inhaled powder
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled powder of fenoterol
Study: 28807017
Drug: Metronidazole treatment
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole treatment
Study: 1318845
Drug: Hydrochlorothiazide 25-50
Normalized name: captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25-50 mg
Study: 26253567
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydrochlorothiazide and amiloride at half doses
Study: 15608809
Drug: Green Prescription
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Prescription physical activity counselling programme
Study: 10395859
Drug: 4% gel
Normalized name: Nicomide-T 4% Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% gel (Conceptrol)
Study: 17717913
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy with diclofenac sodium, Leflunomide and prednisone
Study: 11318886
Drug: Isometheptene mucate,
Normalized name: Isometheptene Mucate, Dichloralphenazone, and Acetaminophen Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isometheptene mucate, dichloralphenazone with acetaminophen
Study: 12548209
Drug: Gentamicin 1.5
Normalized name: HYDROCORTISONE ACEPONATE 1.11 mg in 1 mL / MICONAZOLE NITRATE 17.4 mg in 1 mL / GENTAMICIN 1.5 mg in 1 mL AURICULAR (OTIC) SUSPENSION [EASOTIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 1.5 mg/kg and clindamycin phosphate 900 mg administered every 8 hours
Study: 8902446
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (37 men with significant antisperm antibodies)
Study: 31345267
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of durvalumab, olaparib, and cediranib
Study: 9731851
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1200 mg elemental calcium per day)
Study: 28476440
Drug: Intravenous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous rituximab (375 mg/m2)
Study: 24821885
Drug: Subcutaneous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous rituximab (375 mg/m2, 625 mg/m2, or 800 mg/m2)
Study: 11748103
Drug: L-NMMA infusion
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA infusion in Hyperthyroidism (H)
Study: 21118280
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 60 mg
Study: 23512415
Drug: Insulin Aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Aspart (IA)
Study: 17888133
Drug: Regular Human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Human Insulin (HI)
Study: 6137325
Drug: Chlorthalidone, 100
Normalized name: Chlorthalidone, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone, 100 mg/day
Study: 11570305
Drug: Research into
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Research into defibrinogenating and neuroprotective agents
Study: 20206795
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg with Ginkgo biloba extract 80 mg
Study: 14740127
Drug: Graduated compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graduated compression stockings (GCS) in combination with heparin
Study: 22686415
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (1-g capsule containing at least 900 mg of ethyl esters of n-3 fatty acids daily)
Study: 6367432
Drug: Cefaclor and
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor and Amoxicillin
Study: 8551317
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at subhypnotic doses
Study: 21901396
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg daily and 5-azacytidine 75 mg/m2 daily on days 1-4 and 15-18 of a 28-day cycle
Study: 15951475
Drug: Conventional dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional dipyridamole tablets (two 100 mg tablets + 81 mg aspirin)
Study: 8273981
Drug: Aspirin 324
Normalized name: aspirin 324 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 324 mg/d
Study: 8273981
Drug: Aspirin 1300
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 1300 mg/d
Study: 22584491
Drug: Mg Pidolate
Normalized name: Pidolic acid
DrugBank: Pidolic acid (DB03088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg Pidolate (MgP) 3.0 g/day for 30 days (equivalent to 260 mg of Mg element)
Study: 1999002
Drug: 250-mg flutamide
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-mg flutamide tablets three times daily
Study: 335794
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thiazide and methyldopa (regimen A)